← Home

CU6

Healthcare & BiotechPULLBACK

$2.230

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted
NIBInvestment banks+$5.6M
RetailRetail · context+$3.9M
MMMarket makers+$2.0M
WAWealth & advisers+$1.4M
ResResource specialists+$196k

5d return

-3.9%

20d return

+6.2%

60d return

-23.1%

RSI 14

42.5

vs 52w high

-60.9%

vs 52w low

+22.9%

SMA 20

Below

SMA 50

Below

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Closest correlates
Pearson r on log returns, window: 42d
  • ILTr=0.76, window: 42d
  • NPMr=0.74, window: 42d
  • NVXr=0.73, window: 42d
  • SHNr=0.68, window: 42d
  • DROr=0.64, window: 42d
Announcements — last 30 days
  • 2026-07-16Initial Director's Interest Notice - Rossiter
  • 2026-07-16Allison Rossiter joins Clarity Board of Directors
  • 2026-07-08PSsubstantial_holderCeasing to be a substantial holder

    JPMorgan Chase unwound its substantial holding in Clarity Pharmaceuticals via systematic loan returns and modest spot sales on 29 June–2 July, ceasing ~1.3m shares of net exposure. The exit reflects routine portfolio management rather than loss of confidence, given the minimal selling (small net reduction from 19.2m base) and securities-lending mechanics dominating the transaction.

  • 2026-07-07PSsubstantial_holderCeasing to be a substantial holder

    Vanguard Group exited its substantial holder position in Clarity Pharmaceuticals via a large single sale on 1 July 2026, reducing stake from ~5.8% to 4.751%. The exit follows six months of mixed buying and selling, suggesting passive rebalancing rather than conviction-driven thesis abandonment.